baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

INFLARX N.V. EO 0,12/ NL0012661870 /

8/30/2024 4:06:28 PM	Chg. +0.0450	Volume	Bid9:56:43 PM	Ask9:56:43 PM	High	Low
1.4200EUR	+3.27%	200 Turnover: 297.6000	-Bid Size: -	-Ask Size: -	1.4880	1.4200

GlobeNewswire 8/8 InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8/1 InflaRx to Report Second Quarter 2024 Results on August 8, 2024

GlobeNewswire 7/30 InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Huma...

GlobeNewswire 6/24 InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel ...

GlobeNewswire 6/5 InflaRx Hosts R&D Event Highlighting the Promise of INF904

GlobeNewswire 5/21 InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Poten...

GlobeNewswire 5/8 InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 4/30 InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2...

GlobeNewswire 4/24 InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

GlobeNewswire 4/16 Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...

GlobeNewswire 3/22 Theratechnologies Appoints Jordan Zwick to its Board of Directors

GlobeNewswire 3/21 InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

GlobeNewswire 3/19 InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

GlobeNewswire 2/22 InflaRx Appoints Jan Medina as Head of Investor Relations

GlobeNewswire 1/25 InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Acc...

GlobeNewswire 1/4 InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with...

GlobeNewswire 11/6/2023 InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

GlobeNewswire 11/1/2023 InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 9/11/2023 InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C...

GlobeNewswire 8/30/2023 InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill ...

GlobeNewswire 3/24/2022 InflaRx Reports Full Year 2021 Financial and Operating Results

GlobeNewswire 3/17/2022 InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hi...

GlobeNewswire 3/8/2022 InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentat...

GlobeNewswire 2/28/2022 InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa

GlobeNewswire 2/16/2022 InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous C...

INFLARX N.V. EO 0,12/ NL0012661870 /

If you wish to receive reply to your feedback, please provide your email address.